OC
OLMA icon

Oppenheimer & Co’s Olema Pharmaceuticals OLMA Stock Holding History

Oppenheimer & Co’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,500
Closed -$238K – 1765
2025
Q4 		$238K Buy
+9,500
New +$169K ﹤0.01% 1365

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Oppenheimer & Co's OLMA Position: Q1 2026 in Review

Oppenheimer & Co sold out of Olema Pharmaceuticals (OLMA) in Q1 2026, closing a stake of 9,500 shares — an estimated $238K sold.

Oppenheimer & Co first reported a position in OLMA in Q4 2025 and held it in 1 quarter. The position peaked at $238K in Q4 2025. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • Oppenheimer & Co reported no remaining Olema Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Oppenheimer & Co sold 9,500 Olema Pharmaceuticals shares in Q1 2026, an estimated $238K.
  • Oppenheimer & Co first reported a position in Olema Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Oppenheimer & Co's Olema Pharmaceuticals position peaked at $238K in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.